Biodistribution and Dosimetry of Indigenous 131I-Rituximab in B-Cell Lymphoma: Pilot Study estimating patient specific dose comparing two different dosimetric methods.

CONCLUSION: The indigenous product demonstrated kinetics similar in lines with that of approved commercially available radiopharmaceuticals, with advantage of less HAMA (Human Anti Mouse Antibody) response due to the pharmaceutical being a chimeric antibody rather than murine antibody and hence could be safely administered in clinical settings. In none of the organs there was dose limiting radiation exposure (≥ 20Gy) at the proposed therapeutic doses of this indigenous 131I labeled rituximab product. PMID: 30413603 [PubMed - as supplied by publisher]
Source: Journal of Nuclear Medicine Technology - Category: Nuclear Medicine Tags: J Nucl Med Technol Source Type: research